ABX-CRO wholeheartedly congratulates ITM (Isotope Technologies Munich) to the successful outcome of the COMPETE study (ITM-11 (n.c.a. 177Lu-DOTATOC) in GEP-NET)
The success of COMPETE, marks another milestone in ABX-CRO´s unique track record designing and conducting complex molecular radiotherapy and molecular imaging agents. ITM (Isotope Technologies Munich) recently announced the positive topline results from the Phase 3 COMPETE trial involving ITM-11, a novel targeted radiopharmaceutical therapy. The trial showed promising results in patients with Grade 1 or Grade 2 GEP-NETs.
This development could pave the way for a new standard of care in the management of GEP-NETs.
ABX-CRO wholeheartedly congratulates ITM (Isotope Technologies Munich) to the successful outcome of the COMPETE study (ITM-11 (n.c.a. 177Lu-DOTATOC) in GEP-NET)
The success of COMPETE, marks another milestone in ABX-CRO´s unique track record designing and conducting complex molecular radiotherapy and molecular imaging agents. ITM (Isotope Technologies Munich) recently announced the positive topline results from the Phase 3 COMPETE trial involving ITM-11, a novel targeted radiopharmaceutical therapy. The trial showed promising results in patients with Grade 1 or Grade 2 GEP-NETs.
This development could pave the way for a new standard of care in the management of GEP-NETs.
Find the original press release from ITM here